Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 14

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 14
---
the “Closing”). The Exchange Ratio is calculated using the relative company valuations of each of MIRA and SKNY where the MIRA share value is calculated on an as-issued basis and the SKNY share value is calculated on a fully diluted basis to include all issued SKNY options and warrants. After giving effect to the Closing, the SKNY holders will hold not more than 50% of the shares of the combined company.

Under the Exchange Ratio formula described in the Merger Agreement, immediately following the Merger, the pre-Merger equity holders of SKNY are expected to hold approximately 50% of the outstanding shares of MIRA Common Stock and the pre-Merger equity holders of MIRA are expected to hold approximately 50% of the outstanding shares of MIRA Common Stock, in each case, on a fully diluted basis using the treasury stock method. The Exchange Ratio formula is based upon the relative values of MIRA and SKNY, as determined by Moore Financial Consulting, or Moore, as more fully described in the section titled “ The Merger Agreement—Merger Consideration and Exchange Ratio.” As a condition to Closing, on the Effective Time, SKNY must hold at least $5 million in either cash, marketable securities or a combination of cash and marketable securities. At the Effective Time, MIRA’s stockholders will continue to own and hold their existing shares of MIRA Common Stock. Following the Merger, MIRA’s shares will continue to be listed on the Nasdaq under the symbol “MIRA”.

Q: What will happen to MIRA if, for any reason, the Merger does not close?

A:If, for any reason, the Merger does not close, the board of directors of MIRA (the “MIRA Board”) may elect to, among other things, attempt to complete another strategic transaction similar to the Merger.

Q: Why are the two companies proposing to merge?

A:The Merger will result in a biopharmaceutical company focused on the development and potential commercialization of several novel, potentially first-in-class product candidates targeting multiple therapeutic areas, including smoking cessation, obesity, pain management, depression, post-traumatic stress disorder (PTSD), and cognitive impairment. For a discussion of MIRA’s reasons for the Merger, please see the section titled “ The Merger— Background of the Merger.”

| 3 |

Q: Why am I receiving this proxy statement?

A:You are receiving this proxy statement because you have been identified as a holder